TORNTPHARMNSETorrent Pharmaceuticals Limited· PharmaceuticalsHighPositive
Announced Fri, 13 Feb · 17:10 IST

Torrent Pharmaceuticals Limited has informed the Exchange regarding 'Dividend Payment Date'.

Corporate Actions View source PDF

TORNTPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Torrent Pharmaceuticals' board approved an interim dividend of ₹29 per share (580% on face value of ₹5), with payment expected on or around March 6, 2026. The company also reported Q3 FY26 consolidated revenue of ₹3,303 crore, up 18% year-on-year, with operating EBITDA at ₹1,088 crore (33% margin) and net profit of ₹635 crore, up 26% year-on-year. For the first nine months of FY26, revenue grew 14% to ₹9,783 crore and net profit rose 26% to ₹1,774 crore. The company also completed its acquisition of a 48.8% controlling stake in JB Chemicals & Pharmaceuticals, effective January 21, 2026, with a proposed merger swap ratio of 51 Torrent shares for every 100 JB Pharma shares. India revenues grew 14% to ₹1,798 crore, while Brazil and the US businesses also posted strong double-digit growth.

Likely market impact

Positive for shareholders — strong Q3 profit growth of 26% supports a healthy interim dividend payout, and the completed JB Pharma acquisition makes Torrent the 5th largest pharma company in India, likely boosting long-term scale and earnings. The stock may see near-term support from the dividend, while investor focus will shift to merger approval timelines and integration.